All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Results from a retrospective analysis evaluating the impact of patient- and transplant-related factors on post-transplant outcomes in adult patients with T-cell acute lymphoblastic leukemia (T-ALL) have been published in Bone Marrow Transplantation by El Cheikh et al.1 This analysis included 1,901 adult patients with T-ALL who received allogeneic hematopoietic stem cell transplantation (allo-HSCT) between January 2010 and December 2021, from the European Society for Blood and Marrow Transplantation (EBMT) registry. |
Key learnings |
Advanced age at the time of transplant negatively impacted outcomes: each 10-year increment indicated worse leukemia-free survival (LFS; hazard ratio [HR], 1.11; p = 0.004), graft-versus-host disease (GvHD)-free relapse-free survival (GRFS; HR, 1.06; p = 0.04), overall survival (OS; HR, 1.12; p = 0.002), and non-relapse mortality (NRM; HR, 1.23; p < 0.001), highlighting the need for careful consideration of age when selecting patients for allo-HSCT. |
Transplants performed in more recent years show improved outcomes: each 3-year increment in age was associated with improved GRFS (HR, 0.89; p < 0.001) and OS (HR, 0.9; p = 0.02), and decreased NRM (HR, 0.82; p = 0.008), suggesting that advancements in transplant techniques and supportive care have positively impacted patient outcomes. |
The use of total body irradiation (TBI)-based conditioning was associated with better LFS (HR, 0.79; p = 0.02), GRFS (HR, 0.83; p = 0.04), and reduced relapse incidence (HR, 0.65; p < 0.001), supporting the inclusion of TBI conditioning regimens for suitable patients to enhance long-term outcomes. |
Female-to-male transplants were associated with poorer GRFS (HR, 1.21; p = 0.02) and OS (HR, 1.23; p = 0.048), highlighting the potential need to implement additional monitoring and interventions for this demographic to mitigate risks. |
Your opinion matters
Subscribe to get the best content related to ALL delivered to your inbox